Iktos and Sygnature Discovery announce their collaboration in Artificial Intelligence for de novo  drug design. Under the 3-year agreement, Sygnature will deploy Iktos’s de novo generative design software Makya™, which will be used by Sygnature scientists to facilitate rapid and efficient design of novel compounds and accelerate hit-to-lead/lead optimization, reinforcing Sygnature Discovery’s drug design expertise delivering its integrated drug discovery solutions to its world-wide customer base. Follow the link for the full press release.